Despite high-level endorsement. the number of adaptive Phase II/III trials in rare cancers needs to be improved. with better understanding of their value for clinical decisions in daily practice. This paper describes approaches to trial design in rare cancers. https://mabelandfoxs.shop/product-category/story-book/